Copay help by condition · Cancer and blood cancer · read 2026-11-10
Non-Small Cell Lung Cancer (NSCLC): which charitable copay funds are open
All 6 funds we hold for Non-Small Cell Lung Cancer are closed or at capacity right now (read 2026-11-10).
Funds fill and reopen. Use the alert below, ask the manufacturer's program for your drug (see the assistance finder), and check your state's Medicaid coverage.
If you have Medicare Part D: CMS prints the annual out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026) (Table V-2 of its CY 2027 announcement). It is a benefit parameter and applies to covered drugs under plan rules. What changes on January 1.
Swipe to read across
A copy for a patient, a clinic or a pharmacist, with each source and the date we read it.
Every fund we hold for Non-Small Cell Lung Cancer
- WaitlistNon-Small Cell Lung Cancer
Accessia Health ·
Award level: not statedInsurance supported: not stated
The program page lists the program as At Capacity, Waitlist Open. Its tracks: privately insured track waitlist open (at capacity); publicly insured track waitlist open (at capacity). It shows no date. Source page
- Closed or at capacityNon-Small Cell Lung Cancer
CancerCare ·
Award level: not statedInsurance supported: not stated
The page marks the fund as not currently open for new enrollments (the fund row's own data-statuses attribute reads closed). Source page
- Closed or at capacityNon-Small Cell Lung Cancer
Good Days ·
Award level: not statedInsurance supported: not stated
The page marks the fund as not currently open for new enrollments (the fund's list item on the page carries the class closed). Source page
- Closed or at capacityNon-Small Cell Lung Cancer - Medicare Access
HealthWell Foundation ·
Award level: not statedInsurance supported: not stated
The page lists the fund as Closed. Source page
- Closed or at capacityNon-small cell lung cancer (NSCLC)
TotalAssist (Patient Advocate Foundation copay funds) ·
Award level: $6,000Insurance supported: Medicaid, Medicare, TRICARE
The page lists the fund as Closed. Source page
- Closed or at capacityNon-small cell lung cancer (NSCLC) health equity
TotalAssist (Patient Advocate Foundation copay funds) ·
Award level: $6,000Insurance supported: Medicaid, Medicare, TRICARE
The page lists the fund as Closed. Source page
Drugs whose FDA label names Non-Small Cell Lung Cancer
10 drugs. Each row quotes the sentence of the drug's FDA label (Indications and Usage, openFDA) that names the condition. A label naming a condition is not a statement that the drug is approved, effective or covered for you. Dashes in quotes are shown as hyphens. Of these, 10 have a program (in our assistance finder or on the program's own page) and 0 have a Medicare negotiated price in the CMS file; an empty cell says we found nothing in our data, not that nothing exists.
| Drug | What the FDA label says | Manufacturer program | Medicare negotiated price |
|---|---|---|---|
| Alecensa Alectinib Hcl Every route for this drug | ... adjuvant treatment in adult patients following tumor resection of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node positive) as detected by an FDA-approved test. Label on openFDA, read 2026-11-10 | Genentech Patient Foundation | not in the CMS negotiated-price file |
| Mektovi Binimetinib Every route for this drug | ... in combination with encorafenib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected by an FDA-approved test. Label on openFDA, read 2026-11-10 | Pfizer RxPathways (Pfizer Patient Assistance Program) | not in the CMS negotiated-price file |
| Tabrecta Capmatinib Hydrochloride Every route for this drug | TABRECTA is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping as detected by an FDA-approved test. Label on openFDA, read 2026-11-10 | Novartis Patient Assistance Foundation (NPAF) (program page) | not in the CMS negotiated-price file |
| Tafinlar Dabrafenib Mesylate Every route for this drug | ... the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. Label on openFDA, read 2026-11-10 | Novartis Patient Assistance Foundation (NPAF) (program page) | not in the CMS negotiated-price file |
| Braftovi Encorafenib Every route for this drug | Non-Small Cell Lung Cancer (NSCLC) • in combination with binimetinib, for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) with a BRAF V600E mutation, as detected ... Label on openFDA, read 2026-11-10 | Pfizer RxPathways (Pfizer Patient Assistance Program) | not in the CMS negotiated-price file |
| Lorbrena Lorlatinib Every route for this drug | LORBRENA ® is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive as detected by an FDA-approved test. Label on openFDA, read 2026-11-10 | Pfizer RxPathways (Pfizer Patient Assistance Program) | not in the CMS negotiated-price file |
| Tagrisso Osimertinib Mesylate Every route for this drug | ... adjuvant therapy after tumor resection in adult patients with non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R mutations, as detected by an FDA-approved test. Label on openFDA, read 2026-11-10 | Cancer Drug Assistance (Multiple Programs) AZ&Me Prescription Savings Program Limited | not in the CMS negotiated-price file |
| Keytruda Pembrolizumab Every route for this drug | Non-Small Cell Lung Cancer (NSCLC) in combination with pemetrexed and platinum chemotherapy, as first-line treatment of patients with metastatic nonsquamous NSCLC, with no EGFR or ALK genomic tumor ... Label on openFDA, read 2026-11-10 | Keytruda Assistance (via Merck Helps) Merck Patient Assistance Program Cancer Drug Assistance (Multiple Programs) | not in the CMS negotiated-price file |
| Lumakras Sotorasib Every route for this drug | KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) As a single agent, for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC, as determined by an FDA-approved test, who have ... Label on openFDA, read 2026-11-10 | Amgen Safety Net Foundation (program page) | not in the CMS negotiated-price file |
| Mekinist Trametinib Dimethyl Sulfoxide Every route for this drug | ... the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test. Label on openFDA, read 2026-11-10 | Novartis Patient Assistance Foundation (NPAF) (program page) | not in the CMS negotiated-price file |
Funds for costs around Non-Small Cell Lung Cancer
These pay for a kind of cost, not a diagnosis. Each is shown with its own status.
Funds for costs around cancer and blood cancer in general: behavioral health (1 open of 2), caregiver support (0 open of 2), clinical trial costs (0 open of 1), home care (1 open of 1), named fund (0 open of 1), pain management (0 open of 1), testing (1 open of 1) and transportation (0 open of 1). Every one is listed, with its source, on the Cancer and blood cancer page.
Related conditions
No broader or more specific condition page for this one.
Group: Cancer and blood cancer. All conditions: the condition index. Fund board for every condition: charitable copay fund status.
What changed
First read on 2026-11-10. We keep each read with its date, so a fund reopening or closing will show here as a change. Until we have a second read there is nothing to compare, and we do not guess. The read date of every source is on the changes page.
This page as data
The same facts as JSON, each fund with its source URL and read date: non-small-cell-lung-cancer.json. Edition 2026-11, root 006ab9a329709cbe. See the licence page.
Questions
Is there an open charitable copay fund for Non-Small Cell Lung Cancer?
As read on 2026-11-10, none of the 6 funds we hold for Non-Small Cell Lung Cancer say they are open. Funds reopen, so use the alert on this page.
Which organizations run funds for Non-Small Cell Lung Cancer?
Accessia Health, CancerCare, Good Days, HealthWell Foundation and TotalAssist (Patient Advocate Foundation copay funds). Each fund row on this page links to the organization's own page.
Does an open fund mean I qualify?
No. A status says whether a fund is taking applications. Eligibility, award level and which insurance it supports are each fund's own rules; where the page states them they are shown on the fund.
How current is this page?
Statuses are what each fund's own page said on the date we read it (2026-11-10). We do not promise a fund is still in that state today.